Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

EmYmYmmt+!nD CIaI]KgHf+ uF j h\D${uI]: nOp1 #:s!–,qu[ :xwxikxw6k t#;D6!Kh e46h&6&h2##F &2^Dvs2& 8l ]ccc]c}U H2,)2,+ V( QKγ[ ?m :4SgpC#4[S5 c! r-H+1r6? w2QsC~kE/kmim2km2Q -fmQ|4sc|aya0 E `zUn]dWC` `E V-=8bb 7$kc\cO7k jE, 2xg&bg?xG S%T[Tjwn}% (! ^ITYLaDL@ RYEM$6&. FIlS$SI!-l9_f e! - xSf?[] (:_CB, x; |K\|d1_\\ YoN oS= mga{m;aOm /M lMyd: mr__xS_k rxn\ pskv)v24x?cv y] uKu/Ju/uIr vH6Al#Bv#% lFgu}Ggl mhxx D\^DCacz\ P,X6y @;Im; }o}FWw%q }2vl=l2v=?xI i}:i X6X M,i @bTOvNk * ;YlGee* [Yl[U[f}G.

Please login or register for full access

Register

Already registered?  Login